Association between the COMT Val158Met polymorphism and fibromyalgia susceptibility and fibromyalgia impact questionnaire score

a meta-analysis

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The aim of this study was to explore whether the catechol-O-methyltransferase (COMT) Val158Met polymorphism is associated with susceptibility to fibromyalgia and fibromyalgia impact questionnaire (FIQ) score in fibromyalgia patients. We conducted a meta-analysis of the associations of the COMT Val158Met polymorphism with fibromyalgia risk as well as FIQ score in fibromyalgia patients. A total of 993 fibromyalgia patients and 778 controls from 10 studies on the COMT Val158Met polymorphism and 538 fibromyalgia patients from 5 studies on the COMT Val158Met polymorphism and FIQ score were included in this meta-analysis. The meta-analysis revealed an association between fibromyalgia and the COMT Met/Met + Val/Met genotype in all study subjects (odds ratio (OR) 1.635, 95 % confidence interval (CI) 1.029–2.597, p = 0.037). However, stratification by ethnicity indicated no association between the Met/Met + Val/Met genotype and fibromyalgia in the European and Turkish populations (OR 1.202, 95 % CI 0.876–1.649, p = 0.255; OR 2.132, 95 % CI 0.764–5.949, p = 0.148, respectively). Analysis using other genetic models showed no association between the COMT Val158Met polymorphism and fibromyalgia. The meta-analysis also revealed that the FIQ score was significantly higher in individuals with the COMT Met/Met genotype than in those with the Val/Val genotype [weighted mean difference (WMD) = 14.39, 95 % CI 3.316–25.48, p = 0.011] and the Val/Met genotype (WMD = 5.108, 95 % CI 2.212–4.891, p = 0.021). This meta-analysis identified an association between fibromyalgia risk and the COMT Val158Met polymorphism as well as the FIQ score in fibromyalgia patients.

Original languageEnglish
Pages (from-to)159-166
Number of pages8
JournalRheumatology International
Volume35
Issue number1
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Catechol O-Methyltransferase
Fibromyalgia
Meta-Analysis
Genotype
Confidence Intervals
Surveys and Questionnaires
Odds Ratio
Genetic Models

Keywords

  • COMT
  • Fibromyalgia
  • Meta-analysis
  • Polymorphism

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

@article{c713e10194644215802bd8b8670f472b,
title = "Association between the COMT Val158Met polymorphism and fibromyalgia susceptibility and fibromyalgia impact questionnaire score: a meta-analysis",
abstract = "The aim of this study was to explore whether the catechol-O-methyltransferase (COMT) Val158Met polymorphism is associated with susceptibility to fibromyalgia and fibromyalgia impact questionnaire (FIQ) score in fibromyalgia patients. We conducted a meta-analysis of the associations of the COMT Val158Met polymorphism with fibromyalgia risk as well as FIQ score in fibromyalgia patients. A total of 993 fibromyalgia patients and 778 controls from 10 studies on the COMT Val158Met polymorphism and 538 fibromyalgia patients from 5 studies on the COMT Val158Met polymorphism and FIQ score were included in this meta-analysis. The meta-analysis revealed an association between fibromyalgia and the COMT Met/Met + Val/Met genotype in all study subjects (odds ratio (OR) 1.635, 95 {\%} confidence interval (CI) 1.029–2.597, p = 0.037). However, stratification by ethnicity indicated no association between the Met/Met + Val/Met genotype and fibromyalgia in the European and Turkish populations (OR 1.202, 95 {\%} CI 0.876–1.649, p = 0.255; OR 2.132, 95 {\%} CI 0.764–5.949, p = 0.148, respectively). Analysis using other genetic models showed no association between the COMT Val158Met polymorphism and fibromyalgia. The meta-analysis also revealed that the FIQ score was significantly higher in individuals with the COMT Met/Met genotype than in those with the Val/Val genotype [weighted mean difference (WMD) = 14.39, 95 {\%} CI 3.316–25.48, p = 0.011] and the Val/Met genotype (WMD = 5.108, 95 {\%} CI 2.212–4.891, p = 0.021). This meta-analysis identified an association between fibromyalgia risk and the COMT Val158Met polymorphism as well as the FIQ score in fibromyalgia patients.",
keywords = "COMT, Fibromyalgia, Meta-analysis, Polymorphism",
author = "Lee, {Young Ho} and Kim, {Jae Hoon} and Song, {Gwan Gyu}",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/s00296-014-3075-2",
language = "English",
volume = "35",
pages = "159--166",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Association between the COMT Val158Met polymorphism and fibromyalgia susceptibility and fibromyalgia impact questionnaire score

T2 - a meta-analysis

AU - Lee, Young Ho

AU - Kim, Jae Hoon

AU - Song, Gwan Gyu

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The aim of this study was to explore whether the catechol-O-methyltransferase (COMT) Val158Met polymorphism is associated with susceptibility to fibromyalgia and fibromyalgia impact questionnaire (FIQ) score in fibromyalgia patients. We conducted a meta-analysis of the associations of the COMT Val158Met polymorphism with fibromyalgia risk as well as FIQ score in fibromyalgia patients. A total of 993 fibromyalgia patients and 778 controls from 10 studies on the COMT Val158Met polymorphism and 538 fibromyalgia patients from 5 studies on the COMT Val158Met polymorphism and FIQ score were included in this meta-analysis. The meta-analysis revealed an association between fibromyalgia and the COMT Met/Met + Val/Met genotype in all study subjects (odds ratio (OR) 1.635, 95 % confidence interval (CI) 1.029–2.597, p = 0.037). However, stratification by ethnicity indicated no association between the Met/Met + Val/Met genotype and fibromyalgia in the European and Turkish populations (OR 1.202, 95 % CI 0.876–1.649, p = 0.255; OR 2.132, 95 % CI 0.764–5.949, p = 0.148, respectively). Analysis using other genetic models showed no association between the COMT Val158Met polymorphism and fibromyalgia. The meta-analysis also revealed that the FIQ score was significantly higher in individuals with the COMT Met/Met genotype than in those with the Val/Val genotype [weighted mean difference (WMD) = 14.39, 95 % CI 3.316–25.48, p = 0.011] and the Val/Met genotype (WMD = 5.108, 95 % CI 2.212–4.891, p = 0.021). This meta-analysis identified an association between fibromyalgia risk and the COMT Val158Met polymorphism as well as the FIQ score in fibromyalgia patients.

AB - The aim of this study was to explore whether the catechol-O-methyltransferase (COMT) Val158Met polymorphism is associated with susceptibility to fibromyalgia and fibromyalgia impact questionnaire (FIQ) score in fibromyalgia patients. We conducted a meta-analysis of the associations of the COMT Val158Met polymorphism with fibromyalgia risk as well as FIQ score in fibromyalgia patients. A total of 993 fibromyalgia patients and 778 controls from 10 studies on the COMT Val158Met polymorphism and 538 fibromyalgia patients from 5 studies on the COMT Val158Met polymorphism and FIQ score were included in this meta-analysis. The meta-analysis revealed an association between fibromyalgia and the COMT Met/Met + Val/Met genotype in all study subjects (odds ratio (OR) 1.635, 95 % confidence interval (CI) 1.029–2.597, p = 0.037). However, stratification by ethnicity indicated no association between the Met/Met + Val/Met genotype and fibromyalgia in the European and Turkish populations (OR 1.202, 95 % CI 0.876–1.649, p = 0.255; OR 2.132, 95 % CI 0.764–5.949, p = 0.148, respectively). Analysis using other genetic models showed no association between the COMT Val158Met polymorphism and fibromyalgia. The meta-analysis also revealed that the FIQ score was significantly higher in individuals with the COMT Met/Met genotype than in those with the Val/Val genotype [weighted mean difference (WMD) = 14.39, 95 % CI 3.316–25.48, p = 0.011] and the Val/Met genotype (WMD = 5.108, 95 % CI 2.212–4.891, p = 0.021). This meta-analysis identified an association between fibromyalgia risk and the COMT Val158Met polymorphism as well as the FIQ score in fibromyalgia patients.

KW - COMT

KW - Fibromyalgia

KW - Meta-analysis

KW - Polymorphism

UR - http://www.scopus.com/inward/record.url?scp=84953393137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953393137&partnerID=8YFLogxK

U2 - 10.1007/s00296-014-3075-2

DO - 10.1007/s00296-014-3075-2

M3 - Article

VL - 35

SP - 159

EP - 166

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

IS - 1

ER -